| Schedule of Fair Value Breakdown |
The table below presents the fair value breakdown as of September 30, 2026: | | | Tranche A Note | | | Tranche B Note | | | Total | | | | | Amount | | | Accrued Interest | | | Fair Value | | | Amount | | | Accrued Interest | | | Fair Value | | | Fair Value | | | Notes | | $ | 7,675 | | | $ | 19,608 | | | $ | 18,716 | | | $ | 7,993 | | | $ | 20 | | | $ | 4,591 | | | $ | 23,307 | | | Warrants | | | - | | | | - | | | | - | | | | 207 | | | | - | | | $ | 97 | | | $ | 97 | | | Royalty Purchase Agreement payment | | | - | | | | - | | | | - | | | | - | | | | - | | | $ | 1,749 | | | $ | 1,749 | | | September 30, 2026 | | | | | | | | | | $ | 18,716 | | | | | | | | - | | | $ | 6,437 | | | $ | 25,153 | |
|
| Schedule of Fair Value Composition |
The table below represents the fair value composition of the Tranche B Note: | | | September 30, 2026 | | | December 31, 2025 | | | | | Short term | | | Long term | | | Total | | | Short term | | | Long term | | | Total | | | Tranche B Note | | $ | 4,591 | | | $ | - | | | $ | 4,591 | | | $ | 11,473 | | | $ | - | | | $ | 11,473 | | | Warrant | | $ | - | | | $ | 97 | | | $ | 97 | | | $ | - | | | $ | 850 | | | $ | 850 | | | Royalty Purchase Agreement | | $ | 944 | | | $ | 805 | | | $ | 1,749 | | | $ | 1,072 | | | $ | 1,137 | | | $ | 2,209 | | | Total | | $ | 5,535 | | | $ | 902 | | | $ | 6,437 | | | $ | 12,545 | | | $ | 1,987 | | | $ | 14,532 | |
|
| Schedule of Scilex Transaction |
The table below represents the fair value cycle of 2023 Scilex Transaction and 2024 Refinancing throughout December 31, 2025 and September 30, 2026: | | | Tranche A | | | Tranche B | | | Total | | | Balance as of December 31, 2024 | | $ | 16,486 | | | $ | 18,322 | | | $ | 34,808 | | | Amounts receivable from the royalty agreement (*) | | | - | | | | (1,640 | ) | | | (1,640 | ) | | Principal payments | | | - | | | | (9,875 | ) | | | (9,875 | ) | | Proceeds from the sale of Subsequent Penny Warrants | | | (28,500 | ) | | | - | | | | (28,500 | ) | | Interest payments | | | - | | | | (1,845 | ) | | | (1,845 | ) | | Change in fair value | | | 35,077 | | | | 9,570 | | | | 44,647 | | | Balance as of December 31, 2025 | | | 23,063 | | | | 14,532 | | | | 37,595 | | | Amounts receivable from the royalty agreement (*) | | | - | | | | (1,118 | ) | | | (1,118 | ) | | Principal payments | | | - | | | | (7,132 | ) | | | (7,132 | ) | | Interest payments | | | - | | | | (764 | ) | | | (764 | ) | | Change in fair value (**) | | | (4,347 | ) | | | 919 | | | | (3,428 | ) | | Balance as of September 30, 2026 | | $ | 18,716 | | | $ | 6,437 | | | $ | 25,153 | | | (*) | As of September 30, 2026 and December 31, 2025, $773 and $449, respectively, were included under prepaid expenses and other current assets. | | (**) | During the nine months ended September 30, 2026, the Company received an extension fee of $1,000 from Scilex in consideration for the extension of the maturity of the Tranche A Note and the Tranche B Note. The extension fee is presented separately within “Financial income, net” (see Note 15) and is not included in the change in fair value above. See “Developments during the nine months ended September 30, 2026” above. |
|